Ernexa Therapeutics Inc. Depreciation
Ernexa Therapeutics Inc. (ERNA) reported Depreciation of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-13
- Ernexa Therapeutics Inc. depreciation for the quarter ending 2021-03-31 was $25.16K, a 9.41% increase year-over-year.
- Ernexa Therapeutics Inc. depreciation for the quarter ending 2020-03-31 was $23.00K.
- Ernexa Therapeutics Inc. depreciation for the quarter ending 2018-12-31 was $2.35M, a 15.98% increase year-over-year.
- Ernexa Therapeutics Inc. depreciation for the quarter ending 2018-09-30 was $2.00K, a 66.67% decline year-over-year.
- Ernexa Therapeutics Inc. depreciation for fiscal 2025 was $100.00K, a 0.00% change from fiscal 2024.
- Ernexa Therapeutics Inc. depreciation for fiscal 2024 was $100.00K, a 0.00% change from fiscal 2023.
- Ernexa Therapeutics Inc. depreciation for fiscal 2023 was $100.00K, a 50.00% decline from fiscal 2022.
- Ernexa Therapeutics Inc. depreciation for fiscal 2022 was $200.00K, a 70.94% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-03-13 | ||||
| 2024-12-31 | $100.00K 10-K · filed 2026-03-13 | ||||
| 2023-12-31 | $100.00K 10-K · filed 2025-03-12 | ||||
| 2022-12-31 | $200.00K 10-K · filed 2024-03-14 | $161.00K 10-K · filed 2023-03-20 | |||
| 2021-12-31 | $117.00K 10-K · filed 2023-03-20 | ||||
| 2021-03-31 | $25.16K 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | $98.00K 10-K/A · filed 2022-07-01 | $1.19M 10-K · filed 2021-03-11 | |||
| 2020-03-31 | $23.00K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | $2.36M 10-K · filed 2021-03-11 | ||||
| 2018-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $2.35M derived: sum of 2 quarters · filed 2020-03-19 | $2.38M derived: sum of 3 quarters · filed 2020-03-19 | $2.38M 10-K · filed 2020-03-19 | |
| 2018-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $23.00K derived: sum of 2 quarters · filed 2018-11-09 | $30.00K 10-Q · filed 2018-11-09 | $2.06M derived: sum of 4 quarters · filed 2019-03-22 | |
| 2018-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $28.00K 10-Q · filed 2018-08-06 | $2.06M derived: sum of 3 quarters · filed 2019-03-22 | $2.06M derived: sum of 4 quarters · filed 2019-03-22 | |
| 2018-03-31 | $7.00K 10-Q · filed 2018-05-11 | $2.04M derived: sum of 2 quarters · filed 2019-03-22 | $2.04M derived: sum of 3 quarters · filed 2019-03-22 | ||
| 2017-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $2.03M derived: sum of 2 quarters · filed 2019-03-22 | $2.06M 10-K · filed 2019-03-22 | ||
| 2017-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $30.00K 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | $24.00K 10-Q · filed 2018-08-06 | ||||
| 2016-12-31 | $2.45M 10-K · filed 2018-03-09 | ||||
| 2015-12-31 | $2.06M 10-K · filed 2017-03-09 | ||||
| 2014-12-31 | $1.65M 10-K · filed 2016-03-15 | ||||
| 2013-12-31 | $1.57M 10-K · filed 2015-03-27 | ||||
| 2012-12-31 | $1.85M 10-K · filed 2014-03-31 | ||||
| 2011-12-31 | $2.07M 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |